Quarterly ResultMay 7, 2026, 06:18 AM
Shattuck Labs Completes SL-325 Phase 1 Enrollment; Q1 Net Loss $14.8M
AI Summary
Shattuck Labs announced the completion of enrollment for its Phase 1 clinical trial of SL-325, with comprehensive data anticipated in the second quarter of 2026 and a Phase 2 trial for Crohn's disease expected to begin in the third quarter of 2026. The company also reported a net loss of $14.8 million for the first quarter ended March 31, 2026, with R&D expenses increasing to $10.9 million. As of March 31, 2026, Shattuck Labs held $90.4 million in cash and equivalents, providing a projected cash runway into 2029.
Key Highlights
- SL-325 Phase 1 clinical trial enrollment completed; data expected in Q2 2026.
- Phase 2 clinical trial of SL-325 in Crohn’s disease expected to initiate in Q3 2026.
- Net loss for Q1 2026 was $14.8 million, compared to $13.7 million in Q1 2025.
- Research and Development (R&D) expenses increased to $10.9 million in Q1 2026 from $9.9 million YoY.
- Cash and cash equivalents and short-term investments totaled $90.4 million as of March 31, 2026.
- Current cash and equivalents are expected to fund operations into 2029.